Duality Biologics has announced an exclusive license agreement with GSK (GSK, Financial) for the antibody-drug conjugate (ADC) DB-1324. This agreement grants GSK exclusive rights, excluding mainland China, Hong Kong, and Macau, to develop and commercialize the drug globally.
Under the agreement, GSK will make an upfront payment of $30 million and additional milestone payments before exercising the license. If GSK proceeds with the license, Duality Biologics could receive up to $975 million in milestone payments throughout the development, regulatory, and commercialization phases.
DB-1324 is an innovative ADC molecule developed using Duality Biologics' proprietary DITAC platform, targeting gastrointestinal cancers. It may complement GSK's oncology portfolio through potential combination therapies.
